Early detection of cancer therapy cardiotoxicity by radionuclide angiography: An update

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37:2768‐801.

Article  PubMed  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022;43:4229‐361.

Article  PubMed  Google Scholar 

Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009;53:2231‐47.

Article  CAS  PubMed  Google Scholar 

Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869‐79.

Article  CAS  PubMed  Google Scholar 

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 2012;104:1293‐305.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1–01). J Clin Oncol 2014;32:2159‐65.

Article  PubMed  Google Scholar 

Romond EH, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:3792‐9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol 1991;9:1215‐23.

Article  CAS  PubMed  Google Scholar 

Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 2013;14:72‐80.

Article  CAS  PubMed  Google Scholar 

Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 2013;1:72‐8.

Article  PubMed  Google Scholar 

Wood PW, Choy JB, Nanda NC, Becher H. Left ventricular ejection fraction and volumes: It depends on the imaging method. Echocardiography 2014;31:87‐100.

Article  PubMed  Google Scholar 

Cho GY, Marwick TH, Kim HS, Kim MK, Hong KS, Oh DJ. Global 2-dimensional strain as a new prognosticator in patients with heart failure. J Am Coll Cardiol 2009;54:618‐24.

Article  PubMed  Google Scholar 

de Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, Gotthardt M, Oyen WJ, Kapusta L, et al. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med Technol 2013;41:170‐81.

PubMed  Google Scholar 

Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013;26:493‐8.

Article  PubMed  Google Scholar 

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012;5:596‐603.

Article  PubMed  PubMed Central  Google Scholar 

Jordan JH, Vasu S, Morgan TM, D’Agostino RB Jr, Meléndez GC, Hamilton CA, et al. Anthracycline-associated T1 mapping characteristics are elevated independent of the presence of cardiovascular comorbidities in cancer survivors. Circ Cardiovasc Imaging 2016;9:e004325.

Article  PubMed  PubMed Central  Google Scholar 

Schwartz RG, McKenzie WB, Alexander J, Sager P, D’Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109‐18.

Article  CAS  PubMed  Google Scholar 

Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979;300:278‐83.

Article  CAS  PubMed  Google Scholar 

Choi BW, Berger HJ, Schwartz PE, Alexander J, Wackers FJ, Gottschalk A, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638‐43.

Article  CAS  PubMed  Google Scholar 

Palmeri ST, Bonow RO, Myers CE, Seipp C, Jenkins J, Green MV, et al. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography. Am J Cardiol 1986;58:607‐13.

Article  CAS  PubMed  Google Scholar 

Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: Role of cardiac nuclear imaging. J Nucl Cardiol 2006;13:415‐26.

Article  PubMed  Google Scholar 

Printezi MI, Yousif LIE, Kamphuis JAM, van Laake LW, Cramer MJ, Hobbelink MGG, et al. LVEF by multigated acquisition scan compared to other imaging modalities in cardio-oncology: A systematic review. Curr Heart Fail Rep 2022;19:136‐45.

Article  PubMed  PubMed Central  Google Scholar 

Jones KA, Small AD, Ray S, Hamilton DJ, Martin W, Robinson J, et al. Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy. J Nucl Cardiol 2022;29:581‐9.

Article  CAS  PubMed  Google Scholar 

Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92‐8.

Article  CAS  PubMed  Google Scholar 

Farrell MB, Galt JR, Georgoulias P, Malhotra S, Pagnanelli R, Rischpler C, et al. SNMMI procedure standard/EANM guideline for gated equilibrium radionuclide angiography. J Nucl Med Technol 2020;48:126‐35.

Article  PubMed  Google Scholar 

Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 1987;9:184‐8.

Article  CAS  PubMed  Google Scholar 

Ganz WI, Sridhar KS, Forness TJ. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate. Am J Clin Oncol 1993;16:109‐12.

Article  CAS  PubMed  Google Scholar 

Patel CD, Balakrishnan VB, Kumar L, Naswa N, Malhotra A. Does left ventricular diastolic function deteriorate earlier than left ventricular systolic function in anthracycline cardiotoxicity? Hell J Nucl Med 2010;13:233‐7.

PubMed  Google Scholar 

Suzuki J, Yanagisawa A, Shigeyama T, Tsubota J, Yasumura T, Shimoyama K, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 1999;50:37‐45.

Article  CAS  PubMed  Google Scholar 

Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 2011;130:845‐54.

Article  CAS  PubMed  Google Scholar 

Reuvekamp EJ, Bulten BF, Nieuwenhuis AA, Meekes MR, de Haan AF, Tol J, et al. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA). J Nucl Cardiol 2016;23:824‐32.

Article  CAS  PubMed  Google Scholar 

Klein R, Nadouri D, Osler E, Johnson C, Dent S, Dwivedi G. Diastolic dysfunction can precede systolic dysfunction on MUGA in cancer patients receiving trastuzumab-based therapy. Nucl Med Commun 2019;40:22‐9.

Article  CAS  PubMed  Google Scholar 

Hansen NL, Haarmark C, Zerahn B. Ventricular peak emptying and filling rates measured by gated tomographic radionuclide angiography using a cadmium-zinc-telluride SPECT camera in chemotherapy-naïve cancer patients. J Nucl Cardiol 2020;27:1193‐201.

Article  PubMed  Google Scholar 

Esteves FP, Raggi P, Folks RD, Keidar Z, Askew JW, Rispler S, et al. Novel solid-state-detector dedicated cardiac camera for fast myocardial perfusion imaging: Multicenter comparison with standard dual detector cameras. J Nucl Cardiol 2009;16:927‐34.

Article  PubMed  PubMed Central  Google Scholar 

Jensen MM, Schmidt U, Huang C, Zerahn B. Gated tomographic radionuclide angiography using cadmium-zinc-telluride detector gamma camera; comparison to traditional gamma cameras. J Nucl Cardiol 2014;21:384‐96.

Article  PubMed  Google Scholar 

Zerahn B, Haarmark C. Cardiac CZT-SPECT: More than left ventricular imaging. J Nucl Cardiol 2022;29:1657‐9.

Article 

留言 (0)

沒有登入
gif